Skip to content
OpenCapital
Get started

Harmony Biosciences Holdings, Inc. HRMY Stock-Based Comp

Stock-Based Comp at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$74.5M+10.0%
Alkermes logo
AlkermesALKS
$36.33M+59.3%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$23.44M+0.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$8.75M+29.6%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$8.82M+21.5%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$14.7M+29.2%

Segments

By segment

See full
Rare Neurological Diseases$10.31M-17.2%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Cash & equivalents$589.4M+20.5%
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$1.98B-14.9%
Enterprise value$1.55B-24.9%
P/E13.6×-1.6×
P/S2.2×-0.9×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Harmony Biosciences Holdings, Inc.'s stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harmony Biosciences Holdings, Inc.'s stock-based comp?
Harmony Biosciences Holdings, Inc. (HRMY) reported stock-based comp of $10.62M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s stock-based comp changed year-over-year?
Harmony Biosciences Holdings, Inc.'s stock-based comp decreased by 15.0% year-over-year, from $12.5M to $10.62M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s stock-based comp?
Over 4 years (2021 to 2025), Harmony Biosciences Holdings, Inc.'s stock-based comp has grown at a 30.1% compound annual growth rate (CAGR), from $15.66M to $44.9M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.